The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
An organic heterotricyclic compound that is 1,3,4,6,7,8-hexahydrocyclopenta[g]isochromene substituted by methyl groups at positions 4, 6, 6, 7, 8 and 8 respectively. It is a synthetic musk used as a fragrance in cosmetics.
galaxolide binds to and results in decreased activity of AR protein; galaxolide inhibits the reaction [Metribolone results in increased activity of AR protein]
[galaxolide co-treated with Cyclic AMP] results in decreased activity of CYP17A1 protein; [galaxolide co-treated with Cyclic AMP] results in increased activity of CYP17A1 protein galaxolide results in increased activity of CYP17A1 protein galaxolide results in decreased activity of CYP17A1 protein galaxolide results in decreased expression of CYP17A1 mRNA
galaxolide results in increased expression of EGFR mRNA [galaxolide co-treated with acetyl methyl tetramethyl tetralin] results in increased expression of EGFR mRNA
galaxolide results in increased expression of HIF1A mRNA [galaxolide co-treated with acetyl methyl tetramethyl tetralin] results in increased expression of HIF1A mRNA; galaxolide inhibits the reaction [acetyl methyl tetramethyl tetralin results in increased expression of HIF1A mRNA]; galaxolide inhibits the reaction [acetyl methyl tetramethyl tetralin results in increased expression of HIF1A protein]
[galaxolide results in decreased expression of [HSD3B2 co-treated with CYP21A2]] which results in decreased chemical synthesis of Hydrocortisone; [galaxolide results in decreased expression of [HSD3B2 co-treated with CYP21A2]] which results in decreased chemical synthesis of Progesterone galaxolide results in decreased expression of HSD3B2
galaxolide results in increased expression of IL6 mRNA [galaxolide co-treated with acetyl methyl tetramethyl tetralin] results in increased expression of IL6 mRNA
galaxolide results in increased expression of JAK2 mRNA [galaxolide co-treated with acetyl methyl tetramethyl tetralin] results in increased expression of JAK2 mRNA
[galaxolide co-treated with acetyl methyl tetramethyl tetralin] results in increased expression of MIR155 mRNA; galaxolide inhibits the reaction [acetyl methyl tetramethyl tetralin results in increased expression of MIR155 mRNA]
galaxolide results in decreased expression of MIR17 mRNA [galaxolide co-treated with acetyl methyl tetramethyl tetralin] results in decreased expression of MIR17 mRNA
galaxolide results in decreased expression of MIR19B1 mRNA [galaxolide co-treated with acetyl methyl tetramethyl tetralin] results in decreased expression of MIR19B1 mRNA
[galaxolide co-treated with acetyl methyl tetramethyl tetralin] results in decreased expression of MIR20A mRNA galaxolide results in decreased expression of MIR20A mRNA
galaxolide results in decreased expression of MIR92A1 mRNA [galaxolide co-treated with acetyl methyl tetramethyl tetralin] results in decreased expression of MIR92A1 mRNA
[galaxolide co-treated with acetyl methyl tetramethyl tetralin] results in increased expression of MIR93 mRNA; galaxolide promotes the reaction [acetyl methyl tetramethyl tetralin results in increased expression of MIR93 mRNA]
galaxolide results in increased expression of MMP3 mRNA [galaxolide co-treated with acetyl methyl tetramethyl tetralin] results in increased expression of MMP3 mRNA
[galaxolide co-treated with acetyl methyl tetramethyl tetralin] results in increased expression of MMP9 mRNA; [galaxolide co-treated with acetyl methyl tetramethyl tetralin] results in increased expression of MMP9 protein galaxolide results in increased expression of MMP9 mRNA; galaxolide results in increased expression of MMP9 protein
galaxolide results in increased expression of SNAI1 mRNA [galaxolide co-treated with acetyl methyl tetramethyl tetralin] results in increased expression of SNAI1 mRNA
[galaxolide co-treated with acetyl methyl tetramethyl tetralin] results in increased expression of SNAI2 mRNA; galaxolide promotes the reaction [acetyl methyl tetramethyl tetralin results in increased expression of SNAI2 mRNA] galaxolide results in increased expression of SNAI2 mRNA
galaxolide results in increased expression of STAT3 mRNA [galaxolide co-treated with acetyl methyl tetramethyl tetralin] results in increased expression of STAT3 mRNA
[galaxolide co-treated with acetyl methyl tetramethyl tetralin] results in increased expression of VEGFA mRNA; galaxolide inhibits the reaction [acetyl methyl tetramethyl tetralin results in increased expression of VEGFA protein] galaxolide results in increased expression of VEGFA mRNA
[galaxolide co-treated with acetyl methyl tetramethyl tetralin] results in increased expression of VIM mRNA; galaxolide inhibits the reaction [acetyl methyl tetramethyl tetralin results in increased expression of VIM mRNA] galaxolide results in increased expression of VIM mRNA
acetyl methyl tetramethyl tetralin promotes the reaction [galaxolide results in increased expression of ZEB1 mRNA]; galaxolide promotes the reaction [acetyl methyl tetramethyl tetralin results in increased expression of ZEB1 mRNA]